MENLO PARK, Calif.

加利福尼亚州门洛帕克

,

，

June 25, 2026

2026年6月25日

/PRNewswire/ -- GRAIL, Inc. (Nasdaq:

/美通社/ -- GRAIL, Inc.（纳斯达克：

GRAL

GRAL

), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation.

），一家致力于在癌症可治愈阶段实现早期检测的医疗公司，今日宣布完成此前公布的股权融资，投资方包括三星物产株式会社等三星关联公司。

Pursuant to the definitive agreement, the Samsung entities invested $110 million in GRAIL through the purchase of shares of GRAIL common stock at a price of $70.05 per share, representing a long-term investment in support of GRAIL's growth and international expansion objectives.

根据最终协议，三星实体以每股70.05美元的价格购买GRAIL普通股，向GRAIL投资1.1亿美元，此举代表一项长期投资，旨在支持GRAIL的增长和国际扩张目标。

'This investment from the Samsung entities further strengthens our balance sheet and extends our cash runway as we advance key priorities, including securing regulatory approval and reimbursement for Galleri

三星旗下实体的这笔投资进一步巩固了我们的资产负债表，并延长了我们的现金跑道，同时我们也在推进包括确保Galleri获得监管批准和报销在内的关键优先事项。

®

®

in the United States and expanding access to multi-cancer early detection internationally,' said Aaron Freidin, Chief Financial Officer of GRAIL. 'We are pleased to complete this financing and look forward to deepening our strategic collaboration with Samsung as we work to bring Galleri to patients in Asia.'.

GRAIL首席财务官Aaron Freidin表示：“在美国推进业务，并在国际范围内扩大多癌种早期检测的可及性。我们很高兴完成此次融资，并期待随着我们努力将Galleri带给亚洲患者，进一步深化与三星的战略合作。”

As previously announced, GRAIL and Samsung C&T Corporation intend to collaborate to commercialize the Galleri multi-cancer early detection test in South Korea, with the potential to expand into additional Asian markets, including Japan and Singapore, subject to regulatory approvals and other conditions.

正如先前宣布，GRAIL与三星C&T公司计划合作，在韩国商业化Galleri多癌早期检测测试，并有可能在获得监管批准和其他条件满足的情况下，扩展到包括日本和新加坡在内的其他亚洲市场。

Initial testing will continue to be performed at GRAIL's clinical laboratory in Research Triangle Park, North Carolina..

初步测试将继续在北卡罗来纳州研究三角园区的GRAIL临床实验室进行。

'GRAIL is at a pivotal moment in its mission to transform early cancer detection. This investment in GRAIL, together with the strategic business collaboration, represents a significant milestone in advancing Samsung C&T's vision expanding access to cancer early detection. We are excited to bring the benefits of innovative screening technologies to more people in South Korea and Asia, and believe this partnership will bring us one step closer to GRAIL and Samsung C&T's shared goal of transforming cancer care through earlier detection,' said Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T..

“GRAIL在其变革早期癌症检测的使命中正处于一个关键时刻。对GRAIL的这项投资，加之战略业务合作，标志着三星物产在扩大早期癌症检测可及性的愿景推进过程中迈出了重要一步。我们很高兴能将创新筛查技术的益处带给韩国及亚洲更多民众，并相信这一伙伴关系将使我们离GRAIL与三星物产的共同目标——通过更早检测来变革癌症诊疗——更近一步。”三星物产生命科学业务执行副总裁金载佑表示。

Latham & Watkins LLP served as legal advisor and Morgan Stanley & Co. LLC served as financial advisor to GRAIL. Samsung was advised by Covington & Burling, BKL, and E&Y Han Young (Korea).

Latham & Watkins LLP 担任 GRAIL 的法律顾问，Morgan Stanley & Co. LLC 担任其财务顾问。Samsung 由 Covington & Burling、BKL 和 E&Y Han Young（韩国）提供法律顾问服务。

About Samsung C&T Corporation

关于三星物产株式会社

Samsung C&T Corporation, a dynamic player in industries ranging from construction, trading, fashion and resorts, is actively expanding its portfolio with strategic investments in the fields of biopharmaceutical and life sciences. Since its investment in Samsung Biologics and Samsung Epis Holdings, Samsung C&T continues to invest in innovative technologies and businesses within the bio and healthcare sectors, with the goal of contributing to improving the quality of human life..

三星物产株式会社作为建筑、贸易、时尚和度假村等多个行业的活跃企业，正通过在生物制药和生命科学领域的战略投资积极扩展其业务组合。自投资三星生物制剂和三星爱宝思控股以来，三星物产持续在生物与健康医疗领域投资创新技术和企业，旨在为提升人类生活质量作出贡献。

About GRAIL

关于 GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages.

GRAIL 是一家医疗保健公司，其使命是在癌症可治愈的早期阶段进行检测。GRAIL 致力于利用下一代测序技术、大规模人群临床研究以及最先进的机器学习、软件和自动化技术，在更早阶段检测和识别多种致命癌症类型，从而减轻全球癌症负担。

GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom..

GRAIL基于靶向甲基化的平台能够支持筛查和精准肿瘤学的全程照护，包括对有症状患者的多癌种早期检测、风险分层、微小残留病灶检测、生物标志物分型、治疗及复发监测。GRAIL总部位于加利福尼亚州门洛帕克，并在华盛顿特区、北卡罗来纳州和英国设有分支机构。

For more information, visit

欲了解更多信息，请访问

grail.com

grail.com

.

。

About Galleri

关于 Galleri

®

®

The Galleri

盖勒里

®

®

multi-cancer early detection (MCED) test screens for more than 50 cancer types, including many deadly cancers that currently lack screening options, such as pancreatic, ovarian and liver/bile duct cancers

多癌种早期检测（MCED）测试可筛查50多种癌症，包括许多目前缺乏筛查选项的致命性癌症，如胰腺癌、卵巢癌和肝癌/胆管癌。

1

1

. The Galleri test is the only MCED test clinically proven through a randomized controlled trial to increase earlier cancer detection (Stage I-III) and reduce Stage IV diagnoses - enabling more patients to have access to potentially curative treatment options

Galleri检测是唯一通过随机对照试验在临床上证实能够提高早期癌症（I-III期）检出率并减少IV期诊断的MCED检测，从而使更多患者有机会获得潜在治愈性治疗方案。

2

2

. When added to standard-of-care screening, the Galleri test reduced Stage IV diagnosis by more than 20% after the first year of screening across all stageable cancers

当将 Galleri 检测添加到标准护理筛查中时，在第一年的筛查后，所有可分期癌症的 IV 期诊断减少了超过 20%。

2,*

2,*

. The Galleri test increased cancer detection by screening four times versus standard of care screening alone

与仅采用标准筛查相比，Galleri 检测通过四次筛查将癌症检出率提高了四倍

2

2

. The Galleri test has the lowest false positive rate among MCED tests** and the ability to predict the Cancer Signal of Origin with greater than 90% accuracy, helping guide efficient diagnostic evaluation

Galleri 检测在多癌早期检测（MCED）测试中具有最低的假阳性率**，并且能够以超过 90% 的准确率预测癌症信号来源，有助于指导高效的诊断评估

1-

1-

3

3

. The Galleri test is backed by a robust clinical evidence program, with more than 380,000 participants across multiple studies, including the NHS-Galleri trial, the first and only randomized controlled trial for an MCED test. The Galleri test has delivered consistent performance across these studies.

Galleri检测拥有强有力的临床证据支持，涵盖多项研究中的超过38万名参与者，其中包括NHS-Galleri试验——这是首个也是唯一一个针对多癌种早期检测（MCED）检测的随机对照试验。在这些研究中，Galleri检测表现出一致的性能。

The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, cervical or lung cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older..

Galleri 检测需要持有执照的医疗保健提供者开具的处方，并应作为乳腺X线摄影、结肠镜检查、前列腺特异性抗原（PSA）检测、宫颈癌或肺癌筛查等推荐癌症筛查的补充手段。Galleri 检测推荐用于癌症风险升高的成年人，例如50岁或以上的人群。

For more information, visit

更多信息，请访问

galleri.com

galleri.com

.

。

*A statistically significant reduction was not observed in combined stage III–IV diagnoses across three screening rounds for 12 cancer types responsible for around two-thirds of cancer mortality in the US and UK.

在针对美国和英国约占癌症死亡率三分之二的12种癌症进行的三轮筛查中，联合III–IV期诊断并未显示出统计学意义上的显著减少。

**Test performance metrics do not represent results of a head-to-head comparative study. Separate studies have different designs, objectives, and participant populations, which limits the ability to draw conclusions about comparative performance.

**测试性能指标并不代表头对头比较研究的结果。各项独立研究在设计、目标和受试人群方面存在差异，这限制了得出关于比较性能的结论的能力。**

Important Galleri Safety Information

Galleri 重要安全信息

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located.

Galleri 检测推荐用于癌症风险升高的成年人，例如 50 岁或以上的人群。该检测并不能发现所有癌症，应作为医疗保健提供者推荐的常规癌症筛查检测的补充使用。Galleri 检测旨在发现癌症信号并预测癌症信号在体内的位置。

Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment..

不建议在怀孕者、21岁或更年轻的人群中，或正在接受积极癌症治疗的人群中使用该测试。

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer..

结果应由医疗保健提供者结合病史、临床体征和症状进行解读。“未检测到癌症信号”的测试结果并不能排除癌症。“检测到癌症信号”的测试结果需要通过医学上确立的程序（例如影像学检查）进行确认性诊断评估，以确诊癌症。

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur.

如果通过进一步检查未能确诊癌症，这可能意味着并未患癌，或者检查不足以检测到癌症，包括因癌症位于身体其他部位而导致的情况。假阳性（未患癌却检测到癌症信号）和假阴性（患癌却未检测到癌症信号）的检测结果确实可能出现。

.

。

Rx only.

仅限处方使用。

Laboratory/Test Information

实验室/检测信息

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration.

GRAIL临床实验室根据1988年《临床实验室改进修正案》（CLIA）获得认证，并获得美国病理学家学会的认可。Galleri检测由GRAIL开发，其性能特征也由GRAIL确定。Galleri检测尚未获得美国食品药品监督管理局的许可或批准。

The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes..

GRAIL临床实验室根据CLIA法规进行监管，以执行高复杂度检测。Galleri检测旨在用于临床目的。

GRAIL Forward Looking Statements

GRAIL 前瞻性声明

This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as 'aim,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'should,' 'would,' or 'will,' the negative of these terms, and other comparable terminology.

本新闻稿包含前瞻性陈述。在某些情况下，您可以通过诸如“旨在”、“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可以”、“或许”、“计划”、“潜在”、“预测”、“应该”、“将会”或“将”等前瞻性词汇、这些术语的否定形式以及其他类似术语来识别这些陈述。

These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations about future collaborations among us, Samsung entities or Samsung investors including Samsung C&T Corporation, future initial testing, future reimbursement, future potential additional collaborations, our ability to commercialize Galleri in other geographies, and our cash runway and the sufficiency of cash on hand to finance our business and anticipated trends in our business..

这些前瞻性陈述涉及与我们相关的风险、不确定性和假设，可能包括对我们与三星实体或三星投资者（包括三星C&T公司）之间未来合作的预期、未来的初步测试、未来的报销事宜、未来潜在的额外合作、我们在其他地区将Galleri商业化的能力，以及我们的现金跑道和手头现金是否足以支持我们的业务运营及我们业务中的预期趋势。

These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the sections entitled 'Risk Factors' in our Annual Report on Form 10-K for the period ended December 31, 2024 and in our Quarterly Report on Form 10-Q for the period ended September 30, 2025 (the 'Form 10-Q').

这些陈述仅基于我们对未来事件和趋势的当前预期和预测。存在许多重要因素，可能导致我们的实际结果、活动水平、业绩或成就与前瞻性陈述中明示或暗示的内容产生重大且不利的差异，包括在我们截至2024年12月31日止年度的10-K表年度报告以及截至2025年9月30日止季度的10-Q表季度报告（“10-Q表”）中“风险因素”章节下讨论的那些因素及众多相关风险。

Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make..

此外，我们在一个动态且快速变化的环境中运营。新的风险不时出现。我们的管理层无法预测所有风险，我们也无法评估所有因素对我们业务的影响，或任何单一因素或多种因素组合可能在多大程度上导致实际结果、活动水平、业绩或成就与我们可能作出的任何前瞻性陈述中所载内容存在重大不利差异。

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements.

前瞻性陈述涉及未来，因此受到难以预测且许多超出我们控制范围的固有不确定性、风险和情况变化的影响。尽管我们认为前瞻性陈述中表达或暗示的预期和预测是合理的，但我们无法保证未来的结果、活动水平、业绩或成就。

Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events..

我们的实际业绩、财务状况以及在业务战略和运营方面的成功可能与前瞻性陈述中所示存在重大差异。除法律要求外，我们没有义务在本新闻稿发布之日后更新任何前瞻性陈述，以使先前的陈述与实际结果或修订后的预期保持一致，或反映新信息或意外事件的发生。

1

1

Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi:

Klein EA, Richards D, Cohn A, 等. 使用独立验证集对基于靶向甲基化的多癌种早期检测试验进行临床验证. 《肿瘤学年鉴》. 2021年9月;32(9):1167-77. doi:

10.1016/j.annonc.2021.05.806

10.1016/j.annonc.2021.05.806

2

2

Swanton C. NHS-Galleri: Primary Results From a Randomised Controlled Trial to Assess the Clinical Utility of a Multi-Cancer Early Detection (MCED) Test in Population Screening [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 29-June 2.

Swanton C. NHS-Galleri：一项评估多癌种早期检测（MCED）在人群筛查中临床效用的随机对照试验的主要结果[报告]。美国临床肿瘤学会（ASCO）年会；2026年5月29日至6月2日。

3

3

GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]

GRAIL公司。假阳性率。[存档数据：GR-2025-0256]

SOURCE GRAIL, Inc.

来源：GRAIL公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示